- Report
- August 2022
- 1180 Pages
Global
From €5625EUR$5,899USD£4,821GBP
- Report
- November 2022
- 154 Pages
Global
From €4767EUR$5,000USD£4,086GBP
- Report
- December 2019
- 59 Pages
Global
From €3814EUR$4,000USD£3,269GBP
- Report
- August 2022
- 600 Pages
Global
From €2431EUR$2,550USD£2,084GBP
€2860EUR$3,000USD£2,452GBP
- Report
- February 2020
- 600 Pages
Global
From €3242EUR$3,400USD£2,779GBP
€3814EUR$4,000USD£3,269GBP
- Report
- September 2021
- 258 Pages
Global
From €2622EUR$2,750USD£2,247GBP
€5244EUR$5,500USD£4,495GBP
- Report
- July 2019
- 21 Pages
Global
From €596EUR$625USD£511GBP
€1192EUR$1,250USD£1,022GBP
- Report
- February 2022
- 172 Pages
Global
From €2851EUR$2,990USD£2,444GBP
- Report
- November 2022
- 100 Pages
Global
From €2622EUR$2,750USD£2,247GBP
- Report
- September 2019
- 63 Pages
Global
From €4720EUR$4,950USD£4,045GBP
- Report
- February 2023
- 155 Pages
Global
From €2384EUR$2,500USD£2,043GBP
- Report
- October 2021
- 110 Pages
Global
From €6531EUR$6,850USD£5,598GBP
- Report
- November 2021
- 747 Pages
Global
From €3814EUR$4,000USD£3,269GBP
- Report
- July 2023
- 382 Pages
Global
From €3404EUR$3,570USD£2,918GBP
- Report
- April 2023
- 147 Pages
Global
From €5720EUR$5,999USD£4,903GBP
Cancer Monoclonal Antibodies (mAbs) are a type of oncology drug used to treat cancer. They are a type of biologic therapy, which means they are made from living cells. mAbs are designed to target specific proteins on cancer cells, which can help to slow or stop the growth of the cancer. They can be used alone or in combination with other treatments, such as chemotherapy or radiation therapy. mAbs can be used to treat a variety of cancers, including breast, lung, and colorectal cancer.
The Cancer Monoclonal Antibodies market is a rapidly growing segment of the oncology drugs market. mAbs are becoming increasingly popular due to their ability to target specific proteins on cancer cells, which can help to reduce side effects and improve outcomes. Additionally, mAbs are often more cost-effective than other treatments, making them attractive to healthcare providers.
Some of the major companies in the Cancer Monoclonal Antibodies market include Roche, Merck, Bristol-Myers Squibb, Amgen, and Novartis. Show Less Read more